Details of the Drug | DrugMAP

General Information of Drug (ID: DM5Z8ID)

Drug Name

Tabelecleucel

Synonyms

Tab-cel

Indication

Disease Entry	ICD 11	Status	REF
Post-transplant lymphoproliferative disorder	2B32	Phase 3	[1]
Nasopharyngeal carcinoma	2B6B	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

TTD ID: DY4Q6M

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT03394365) Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.